The CABENUVA ASOC workflow

Cabenuva is a complete injectable regimen of cabotegravir and rilpivirine used to replace an existing HIV-1 treatment regimen in eligible people whose virus is already suppressed. It is HIV treatment, not PrEP. A professional gives two injections into gluteal muscles at scheduled visits. Fewer daily pills can be helpful, but maintaining suppression still depends on attendance, laboratory monitoring and an uninterrupted treatment plan if injections stop.

The labeled indication includes adults and adolescents aged 12 or older who weigh at least 35 kg and have HIV RNA below 50 copies/mL on a stable regimen. It also requires no history of treatment failure and no known or suspected resistance to either medicine. The HIV clinician reviews prior regimens and resistance records, rather than relying on one recent viral-load result. Hepatitis B, pregnancy, interacting medicines, liver disease and ability to attend visits also affect the decision. Cabenuva does not treat hepatitis B.

The clinician responsible for HIV care confirms suppression, treatment history and suitability. Do not stop current tablets while a referral, authorization or delivery is pending.

Monthly and every-two-month injection schedules are available. An oral lead-in with both medicines is optional. The every-two-month pathway begins with two initiation visits one month apart before moving to the continuing calendar.

A referring HIV office and an alternative site of care may have different roles. Confirm the prescription, supply route, target date, labs, injection record and where urgent questions go. The administration site does not replace the HIV clinician who manages the regimen.

Arrange viral-load testing after the change and continuing treatment-safety review. The team needs a plan for travel, delays, side effects and return to another suppressive regimen if needed.

The schedule is monthly or every two calendar months, not a freely interchangeable eight-week interval. Tell both the HIV clinician and administration team immediately if a visit may be more than seven days late. Oral coverage or a different injection restart may be needed. If Cabenuva stops, another fully suppressive regimen must start on the label’s timeline: no later than one month after the final monthly injections or two months after the final every-two-month injections. Viral-load follow-up remains necessary.

The clinician responsible for HIV care confirms suppression, treatment history and suitability. Do not stop current tablets while a referral, authorization or delivery is pending.

Monthly and every-two-month injection schedules are available. An oral lead-in with both medicines is optional. The every-two-month pathway begins with two initiation visits one month apart before moving to the continuing calendar.

A referring HIV office and an alternative site of care may have different roles. Confirm the prescription, supply route, target date, labs, injection record and where urgent questions go. The administration site does not replace the HIV clinician who manages the regimen.

Arrange viral-load testing after the change and continuing treatment-safety review. The team needs a plan for travel, delays, side effects and return to another suppressive regimen if needed.

CABENUVA is HIV treatment, not PrEP. The HIV clinician must verify eligibility, manage the regimen and provide the exact order and target date. An administration site may carry out an accepted order while the HIV clinician remains responsible for treatment. Confirm actual clinic capability, sourcing, records and missed-dose responsibility; keep your HIV follow-up and arrange the dose with the receiving clinic.

Bring a complete medicine list, prior ART and resistance records, recent viral-load results and any hepatitis B history. Include acid-reducing medicines if oral rilpivirine is considered, because tablet interactions differ from injection interactions. Confirm who orders and receives labs, who authorizes oral coverage for a missed visit and who can reschedule you. Book the next target date before leaving when possible.

The clinician responsible for HIV care confirms suppression, treatment history and suitability. Do not stop current tablets while a referral, authorization or delivery is pending.

Monthly and every-two-month injection schedules are available. An oral lead-in with both medicines is optional. The every-two-month pathway begins with two initiation visits one month apart before moving to the continuing calendar.

A referring HIV office and an alternative site of care may have different roles. Confirm the prescription, supply route, target date, labs, injection record and where urgent questions go. The administration site does not replace the HIV clinician who manages the regimen.

Arrange viral-load testing after the change and continuing treatment-safety review. The team needs a plan for travel, delays, side effects and return to another suppressive regimen if needed.

Call the HIV clinician and administration site with the exact dates. A delay beyond the permitted window may require oral therapy and clinical reassessment. Never assume the long-lasting medicine makes a gap harmless.

One result requires interpretation with earlier results, timing, adherence and possible interactions. Your HIV clinician decides when to repeat testing and whether resistance assessment or a treatment change is needed. A forum cannot establish that your result is harmless.

Discuss soreness, prior reactions, travel and the need to attend every appointment. Confirm the expected visit process with the site. Neither a standard amount of time off nor a promise of painless injections applies to everyone.